Role of the Akt/mTOR Survival Pathway in Cisplatin Resistance in Ovarian Cancer Cells

Overview

Journal Biochem Biophys Res Commun

Publisher Elsevier

Specialty Biochemistry

Date 2010 Mar 11

PMID 20214883

Citations 84

Authors

Dong-Jun Peng

Juan Wang

Jun-Ying Zhou

Gen Sheng Wu

Affiliations

Soon will be listed here.

Abstract

The mechanism of cisplatin resistance in cancer cells is not fully understood. Here, we show that the Akt/mTOR survival pathway plays an important role in cisplatin resistance in human ovarian cancer cells. Specifically, we found that cisplatin treatment activates the Akt/mTOR survival pathway and that inhibition of this pathway by the PI3K inhibitor LY294002 or knockdown of Akt sensitizes ovarian cancer cells to cisplatin. Furthermore, we generated cisplatin-resistant cells and found that resistant cells express a higher level of activated Akt as compared to their cisplatin sensitive counterparts. Importantly, inhibition of Akt or mTOR sensitized resistant cells to cisplatin-induced apoptosis. Taken together, our data indicate that activation of the Akt/mTOR pathway prevents cisplatin-induced apoptosis, leading to cisplatin resistance. Therefore, our study suggests that cisplatin resistance can be overcome by targeting the Akt/mTOR survival pathway in human ovarian cancer cells.

Citing Articles

Optimized therapeutic potential of Sijunzi-similar formulae for chronic atrophic gastritis via Bayesian network meta-analysis.

Huang M, Luo S, Yang J, Xiong H, Lu X, Ma X EXCLI J. 2024; 23:1185-1207.

PMID: 39421026 PMC: 11484511. DOI: 10.17179/excli2024-7618.

An Overview of Altered Pathways Associated with Sensitivity to Platinum-Based Chemotherapy in Neuroendocrine Tumors: Strengths and Prospects.

Stefano E, Castro F, Ciccarese A, Muscella A, Marsigliante S, Benedetti M Int J Mol Sci. 2024; 25(16).

PMID: 39201255 PMC: 11354135. DOI: 10.3390/ijms25168568.

The Induction of G2/M Phase Cell Cycle Arrest and Apoptosis by the Chalcone Derivative 1C in Sensitive and Resistant Ovarian Cancer Cells Is Associated with ROS Generation.

Salanci S, Vilkova M, Martinez L, Mirossay L, Michalkova R, Mojzis J Int J Mol Sci. 2024; 25(14).

PMID: 39062784 PMC: 11277160. DOI: 10.3390/ijms25147541.

Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation.

Myint K, Balasubramanian B, Venkatraman S, Phimsen S, Sripramote S, Jantra J Pharmaceuticals (Basel). 2024; 17(2).

PMID: 38399413 PMC: 10892566. DOI: 10.3390/ph17020197.

Histone acetylation: a key determinant of acquired cisplatin resistance in cancer.

Natu A, Verma T, Khade B, Thorat R, Gera P, Dhara S Clin Epigenetics. 2024; 16(1):8.

PMID: 38172984 PMC: 10765630. DOI: 10.1186/s13148-023-01615-5.

References

Beale P, Rogers P, Boxall F, Sharp S, Kelland L . BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma. Br J Cancer. 2000; 82(2):436-40. PMC: 2363292. DOI: 10.1054/bjoc.1999.0939. View

Wang J, Zhou J, Zhang L, Wu G . Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells. Cell Cycle. 2009; 8(19):3191-8. PMC: 4063298. DOI: 10.4161/cc.8.19.9751. View

Kandasamy K, Srivastava R . Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res. 2002; 62(17):4929-37. View

Agarwal R, Kaye S . Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003; 3(7):502-16. DOI: 10.1038/nrc1123. View

Cullen K, Newkirk K, Schumaker L, Aldosari N, Rone J, Haddad B . Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cancer Res. 2003; 63(23):8097-102. View

Altomare D, Wang H, Skele K, De Rienzo A, Klein-Szanto A, Godwin A . AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004; 23(34):5853-7. DOI: 10.1038/sj.onc.1207721. View

Dabholkar M, Vionnet J, Yu J, Reed E . Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest. 1994; 94(2):703-8. PMC: 296149. DOI: 10.1172/JCI117388. View

Perego P, Giarola M, Righetti S, Supino R, Caserini C, Delia D . Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res. 1996; 56(3):556-62. View

Johnson S, Shen D, Pastan I, Gottesman M, Hamilton T . Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines. Exp Cell Res. 1996; 226(1):133-9. DOI: 10.1006/excr.1996.0211. View

10.

Go R, Adjei A . Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999; 17(1):409-22. DOI: 10.1200/JCO.1999.17.1.409. View

11.

Boeckman H, Trego K, Turchi J . Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining. Mol Cancer Res. 2005; 3(5):277-85. PMC: 2432110. DOI: 10.1158/1541-7786.MCR-04-0032. View

12.

Hay N . The Akt-mTOR tango and its relevance to cancer. Cancer Cell. 2005; 8(3):179-83. DOI: 10.1016/j.ccr.2005.08.008. View

13.

Tummala M, McGuire W . Recurrent ovarian cancer. Clin Adv Hematol Oncol. 2005; 3(9):723-36. View

14.

Turchi J . Nitric oxide and cisplatin resistance: NO easy answers. Proc Natl Acad Sci U S A. 2006; 103(12):4337-8. PMC: 1450170. DOI: 10.1073/pnas.0601001103. View

15.

Kwong J, Lee J, Wong K, Zhou X, Wong D, Lo K . Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia. 2006; 8(4):268-78. PMC: 1600675. DOI: 10.1593/neo.05502. View

16.

Kuo M, Chen H, Song I, Savaraj N, Ishikawa T . The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev. 2007; 26(1):71-83. DOI: 10.1007/s10555-007-9045-3. View

17.

Kelland L . The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007; 7(8):573-84. DOI: 10.1038/nrc2167. View

18.

Lane D, Robert V, Grondin R, Rancourt C, Piche A . Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells. Int J Cancer. 2007; 121(6):1227-37. DOI: 10.1002/ijc.22840. View

19.

Sarkaria J, Schwingler P, Schild S, Grogan P, Mladek A, Mandrekar S . Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer. J Thorac Oncol. 2007; 2(8):751-7. DOI: 10.1097/JTO.0b013e3180cc2587. View

20.

Fraser M, Bai T, Tsang B . Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer. 2007; 122(3):534-46. DOI: 10.1002/ijc.23086. View